See the DrugPatentWatch profile for Nexlizet
What is Nexlizet (180 mg/10 mg)?
Nexlizet 180 mg/10 mg is an oral prescription medicine used to lower cholesterol. It combines two active ingredients: ezetimibe 180 mg and bempedoic acid 10 mg (in a fixed-dose tablet regimen) [1].
What is it used for?
Nexlizet is prescribed for adults who need additional cholesterol-lowering beyond what they can achieve with diet and statins (or for people who cannot take statins, depending on the clinician’s assessment and local prescribing guidance). It targets cholesterol by reducing absorption of cholesterol in the intestine (ezetimibe) and lowering cholesterol synthesis in the liver (bempedoic acid) [1].
How does the 180 mg/10 mg dosing work?
The 180 mg/10 mg label reflects the combination of the two drugs in one product, with ezetimibe at 180 mg and bempedoic acid at 10 mg per tablet [1]. Because the exact daily regimen can depend on the patient’s other lipid medicines and prescriber instructions, dosing should follow the specific prescription and product directions.
Is there a patent or exclusivity issue around Nexlizet?
For current patent and exclusivity information for Nexlizet, DrugPatentWatch tracks relevant patent landscape details and filings for products in its database. You can check its Nexlizet coverage here: DrugPatentWatch – Nexlizet [1].
What would you want to know next—side effects, pricing, or alternatives?
People often search next for Nexlizet’s common side effects, drug interactions (especially with other cholesterol medicines), and how it compares with similar options (like ezetimibe alone, bempedoic acid alone, or PCSK9 inhibitors). If you tell me what you’re trying to find (dose instructions, side effects, insurance cost, or whether a substitute is available), I can narrow it to that.
Sources:
[1] https://www.drugpatentwatch.com/patent/ezetimibe-bempedoic-acid